At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 2 clinical trial evaluating GSK573719, Tiotropium, and 1 other intervention for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 163 participants across 13 sites.
Detailed Summary
The purpose of this study is to further characterize the dose response of GSK573719 at doses of 15.6 micrograms (mcg) to 125 mcg once daily in patients with chronic obstructive pulmonary disease (COPD). Treatment with doses of GSK573719 dosed twice daily will also be included to further evaluate dosing frequency. Treatment with tiotropium (18 mcg) once daily via the Handihaler will be included as an active control. A placebo treatment will be included in order to evaluate absolute treatment effect of the different doses of GSK573719.
Study Details
Timeline
Interventions
125 mcg once daily
62.5 mcg once daily
31.25 mcg once daily
15.6 mcg once daily
31.25 mcg twice daily
15.6 mcg twice daily
18 mcg once daily
once or twice daily